Crossmark

Benefit–Risk Monitoring of Vaccines Using an Interactive Dashboard: A Methodological Proposal from the ADVANCE Project

Crossref DOI link: https://doi.org/10.1007/s40264-018-0658-y

Published Online: 2018-03-26

Published Print: 2018-08

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Bollaerts, Kaatje https://orcid.org/0000-0001-7704-0527
De Smedt, Tom

Donegan, Katherine

Titievsky, Lina

Bauchau, Vincent
Funding

Funding for this research was provided by:

IMI (n° 115557)
License Information

Text and Data Mining valid from 2018-03-26
More Information

Article History

First Online: 26 March 2018

Compliance with Ethical Standards

:

: The research leading to these results has received support from the Innovative Medicines Initiative Joint Undertaking under ADVANCE Grant agreement n° 115557, resources of which are composed from the European Union’s Seventh Framework Programme (FP7/2007-2013) and EFPIA (European federation of pharmaceutical industries and associations) companies in kind contribution.

: Vincent Bauchau is employed by and owns restricted shares of the GlaxoSmithKline (GSK) group of companies, which is the producer of the vaccine for which simulated data were generated to demonstrate the methodology. Lina Titievsky is an employee and stock owner of Pfizer. Kaatje Bollaerts, Tom de Smedt and Katherine Donegan have no conflicts to declare.

: This article does not contain any studies with human participants performed by any of the authors.